EZH2, enzymatic subunit of PRC2, has been reported to be overexpressed in GBM (Li al., 2013; Suva al., 2009) and is often correlated with metastasis and poor prognosis (Chase and Cross, 2011; Simon and Lange, 2008), suggesting that EZH2 may act as an oncogene, and that targeting EZH2 can be a potential therapeutic approach for pediatric gliomas (Mohammad al., 2017). The gene discussed is EZH2; the disease is glioblastoma.